Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.Cancer Immunology, Immunotherapy : CII|June 3, 2015
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patientsMaria Grazia Cusi, Cirino Botta, Pierpaolo Pastina, et al.The Journal of Allergy and Clinical Immunology|February 2, 2025
BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell featuresClaudia De Pasquale, Fabiana Drommi, Alessia Calabrò, et al.International Journal of Molecular Sciences|July 2, 2021
Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case ReportCirino Botta, Rita Maria Agostino, Vincenzo Dattola, et al.Blood Cancer Discovery|September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activationAnnamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.Oncology Letters|January 23, 2020
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using NivolumabValerio Nardone, Paolo Tini, Pierpaolo Pastina, et al.Journal of Hematology & Oncology|March 23, 2019
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myelomaMaria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, et al.Cancer Biology & Therapy|October 30, 2016
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapseValerio Nardone, Cirino Botta, Michele Caraglia, et al.Leukemia|July 8, 2020
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myelomaMarco Rossi, Emanuela Altomare, Cirino Botta, et al.Journal of Thoracic Disease|December 10, 2017
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patientsPierpaolo Pastina, Valerio Nardone, Stefania Croci, et al.Pageof 10